Unleashing the power of immunotherapy and targeted therapy combinations: Advancing cancer care or discovering unknown toxicities?

Daniel J PrzybylskiJason J BergsbakenJennifer K Piccolo

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)

Future research will be needed to determine appropriate sequencing of TKIs and ICIs after progression on combination therapy. Continued research is necessary to determine optimal dual TKI and immunotherapy options.

Keyphrases

combination therapy
tyrosine kinase
single cell
current status
advanced non small cell lung cancer